HighTower Advisors LLC lowered its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 9.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 413,033 shares of the company’s stock after selling 42,245 shares during the period. HighTower Advisors LLC’s holdings in AstraZeneca were worth $66,715,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in AZN. Amundi grew its stake in shares of AstraZeneca by 6.7% in the second quarter. Amundi now owns 16,422,784 shares of the company’s stock worth $3,114,088,000 after purchasing an additional 1,036,635 shares during the last quarter. Janus Henderson Group PLC increased its holdings in AstraZeneca by 889.9% during the 1st quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock valued at $2,319,947,000 after purchasing an additional 10,742,268 shares during the period. Fisher Asset Management LLC raised its position in AstraZeneca by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 11,501,748 shares of the company’s stock valued at $1,857,187,000 after purchasing an additional 355,456 shares during the last quarter. Royal Bank of Canada raised its position in AstraZeneca by 208.6% during the 1st quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock valued at $2,048,417,000 after purchasing an additional 7,021,126 shares during the last quarter. Finally, Rathbones Group PLC raised its position in AstraZeneca by 106,772.0% during the 1st quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock valued at $1,560,419,000 after purchasing an additional 8,047,406 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.
Analyst Upgrades and Downgrades
AZN has been the topic of a number of recent analyst reports. Wall Street Zen upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Nordea Equity Research upgraded AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Royal Bank Of Canada assumed coverage on AstraZeneca in a report on Tuesday, September 8th. They set an “outperform” rating for the company. Zacks Research upgraded shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. Finally, Deutsche Bank raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $206.67.
Read Our Latest Report on AstraZeneca
AstraZeneca Stock Performance
Shares of AZN opened at $178.78 on Thursday. The company has a 50-day simple moving average of $170.12 and a two-hundred day simple moving average of $180.13. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.01 and a quick ratio of 0.79. The firm has a market capitalization of $277.28 billion, a PE ratio of 25.29, a price-to-earnings-growth ratio of 1.41 and a beta of 0.24. AstraZeneca Plc has a one year low of $153.41 and a one year high of $212.71.
AstraZeneca (NYSE:AZN – Get Free Report) last posted its earnings results on Saturday, October 31st. The company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The firm had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. During the same quarter in the prior year, the business earned $2.38 EPS. The business’s revenue for the quarter was up 6.5% on a year-over-year basis. On average, analysts anticipate that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.
About AstraZeneca
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Featured Articles
- Five stocks we like better than AstraZeneca
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
